Evidence map›Paper›PMID 32719579›Full record

ArticleProcess biochemistry (Barking, London, England)2020

Next generation sequencing and functional pathway analysis to understand the mechanism of action of copper-tolfenamic acid against pancreatic cancer cells.

Myrna Hurtado, Laszlo Prokai, Umesh T Sankpal, Blair Levesque, Rajasekhar Maram, Jaya Chhabra, Deondra T Brown, Raj K Gurung, Alvin A Holder, Jamboor K Vishwanatha and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Process biochemistry (Barking, London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Myrna HurtadoBiochemistry and Cancer Biology, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX, 76107, United States.
Laszlo ProkaiDepartment of Pharmacology and Neuroscience, Institute for Healthy Aging, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX, 76107, United States.
Umesh T SankpalTexas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX, 76107, United States.
Blair LevesqueTexas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX, 76107, United States.
Rajasekhar MaramTexas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX, 76107, United States.
Jaya ChhabraDepartment of Chemistry and Biochemistry, Old Dominion University, Norfolk, VA, 23529, United States.
Deondra T BrownDepartment of Chemistry and Biochemistry, Old Dominion University, Norfolk, VA, 23529, United States.
Raj K GurungDepartment of Chemistry and Biochemistry, Old Dominion University, Norfolk, VA, 23529, United States.
Alvin A HolderDepartment of Chemistry and Biochemistry, Old Dominion University, Norfolk, VA, 23529, United States.
Jamboor K VishwanathaDepartment of Microbiology, Immunology and Genetics, Graduate School of Biomedical Sciences University of North Texas Health Science Center, Fort Worth, TX, 76107, United States.
Riyaz BashaTexas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX, 76107, United States.
Old Dominion University · USUniversity of North Texas Health Science Center · USTexas College · USUniversity of North Texas · US

Funding

AIM-AHEAD Coordinating Center - All Four CoresOT2OD032581 · OD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI Paul Avillach, Bettina M. Beech · 2021 to 2026
$168.7M
Texas Minority Health, Research and Outreach (MiHERO)S21MD012472 · NIMHD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI JAMBOOR K. VISHWANATHA · 2017 to 2026
$18.0M
Texas Center for Minority Health, Education, Research and OutreachU54MD006882 · NIMHD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI JONES, HARLAN PIERRE, VISHWANATHA, JAMBOOR K. · 2017 to 2022
$6.0M
Triple Negative Breast Cancer: Novel Biomarkers and Therapeutic StrategiesP20MD006882 · NIMHD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI VISHWANATHA, JAMBOOR K. · 2012 to 2016
$5.8M
2/2 Pilot Project 2: Langston University-UNTHSC Partnership for Cancer Research and EducationP20CA233391 · NCI · LANGSTON UNIVERSITY · PI HUNTER, TERESSA · 2018 to 2021
$777k
NCI NIH HHS P20 CA233391NIH HHS OT2 OD032581NIMHD NIH HHS P20 MD006882NIMHD NIH HHS S21 MD012472NIMHD NIH HHS U54 MD006882
6 · The paper itself

Abstract

Anti-cancer activity of tolfenamic acid (TA) in preclinical models for pancreatic cancer (PaCa) is well established. Since the dosage for anti-cancer actions of TA is rather high, we recently demonstrated that IC

Indexed as

ApoptosisCopper-tolfenamic acidGene expressionNext generation sequencingPancreatic cancerPathway analysis

Identifiers

PMID32719579
PMCPMC7384693
OpenAlexW2986591745

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.